Study of Physiological and Immunological Factors (FSH, LH, Prolactin, TSH, Free T4, AMH, and Toxoplasma gondii Antibodies activity in Women with Recurrent Miscarriage
DOI:
https://doi.org/10.63939/4mpkvm70Keywords:
recurrent miscarriage, autoantibodies, antiphospholipid, cytokinesAbstract
Background: Recurrent miscarriag (RM), classified as the loss of two or more consecutive pregnancies, is a multifactorial reproductive disorder due to hormonal discrepancies, immunological disorders and pathogenic microorganisms. Fertility hormones including fertility-specific biomarkers, such as FSH, LH, prolactin (Prl), anti-müllerian hormone (AMH), TSH and Free T4 in association with Toxoplasma gondii have been considered essential for adverse pregnancy outcomes. This work focusses on the assessment of physiological and immunological characteristics of female patients with recurrent miscarriage, based on the determination of specific hormonal markers as well as the activity of Toxoplasma gondii antibody.
Objectives: The aim was to explore the relationship between selected reproductive and thyroid hormones (FSH, LH, prolactin, TSH, Free T4 and AMH) and serological activity of Toxoplasma gondii antibodies (IgG, IgM) in women with a history of recurrent miscarriage in relation to relations between these factors regarding pregnancy loss.
Methods: A case–control study Patients were women with RM and age-matched healthy control subjects without previous reproductive pathologies. We used standardized immunoassay methodology to measure serum levels of FSH, LH, prolactin, TSH, Free T4 and AMH. We used enzyme-linked immunosorbent assay (ELISA) to measure Toxoplasma gondii antibody activity. Statistical comparison of differential results between groups and correlations between physiologic and immunologic measures was conducted.
Results: Women with recurrent miscarriage showed significant aberrations in several hormone parameters compared to healthy controls. Higher serum FSH and LH, irregular prolactin secretion and reduced AMH levels were widely recognized indicators of DOR with potentialovulatory dysfunctions. Thyroid indexes of the animals suggested a tendency towards subclinical hypothyroidism with increased levels of TSH and slightly decreased Free T4 in some RM subjects. Moreover, seropositivity to Toxoplasma gondii, in particular high IgG titers, was significantly more common among RM group suggesting past contact with possible immunological consequences. The hormonal imbalances and high levels of Toxoplasma gondii antibodies were positively correlated.
Conclusions: These results unveil a propensity of recurrent miscarriage towards dysregulation of reproductive and thyroid hormonal pathways, combined with an exacerbated immune reaction to Toxoplasma gondii. These results emphasize the importance of full endocrine-immunologic profiling for women with RPL and suggest that a combined strategy of hormonal and infectious workup will improve diagnostic applicability as well as management options.
Keywords: Recurrent miscarriage, FSH, LH, Prolactin, TSH, Free T4, AMH and Toxoplasma gondii
Downloads
References
1. Practice Committee of the American Society for Reproductive Medicine. Infertility and recurrent pregnancy loss defined. Fertil Steril. 2020;113(3):533–5.
2. Regan L, Rai R. Epidemiology and medical causes of miscarriage. Best Pract Res Clin Obstet Gynaecol. 2000;14(5):839–54.
3. Ford HB, Schust DJ. Repeated miscarriage: causes, diagnosis, and treatment. Rev Obstet Gynecol. 2009;2(2):76–83.
4. Li TC, Makris M, Tomsu M, Tuckerman E, Laird S. Recurrent miscarriage: aetiology of chinese medicine in the treatment and management-prospects for its integration within critical care. Hum Reprod Update. 2002;8(5):463–81.
5. Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Müllerian hormone: how to use it in clinical practice? Hum Reprod Update. 2014;20(5):688–701.
6. Dewailly D, Andersen CY, Balen A, et al. Biological and clinical characteristics of anti-Müllerian hormone. Hum Reprod Update. 2014;20(3):370–85.
7. Seckin B, Turkcapar F. Anti-Müllerian hormone and unexplained recurrent miscarriage. J Obstet Gynaecol Res. 2019;45(1):95–102.
8. Bussen S, Steck T. Hyperprolactinaemia as a risk factor for miscarriage. Eur J Obstet Gynecol Reprod Biol. 1999;87(2):159–61.
9. Thiruchelvam U, Willets JM, Masonik HD. Hyperprolactinemia and infertility. Womens Health. 2019; 15:174550651987372.
10. Korevaar TI, Schalekamp-Timmermans S, de Rijke YB, et al. Thyroid dysfunction and miscarriage. J Clin Endocrinol Metab. 2013;98(11):4481–8.
11. orapet ME, Negro Lekakis P. Maternal thyroid dysfunction during pregnancy and preterm delivery. BMJ. 2014;349: g4929.
12. Lazarus JH. Thyroid function in pregnancy. Br Med Bull. 2011; 97:137–48.
13. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965–76.
14. Pappas G, Roussos N, Falagas ME. Global seroprevalence of Toxoplasma gondii. Int J Parasitol. 2009;39(12):1385–94.
15. Zaman M, Taha AM, Al-Dabbagh SA. Toxoplasmosis seroprevalence and recurrent miscarriage. J Infect Dev Ctries. 2020;14(2):170–6.
16. Mor G, Cardenas I. The immune system in pregnancy. Am J Reprod Immunol. 2010;63(6):425–33.
17. Kwak-Kim J, Lee SK, Gilman-Sachs A. Reproductive immunology in RM. Obstet Gynecol Clin North Am. 2014;41(1):117–34.
18. Petroff MG. Immune cross-talk at the maternal–fetal interface. J Reprod Immunol. 2005;68(1–2):1–13.
19. Practice Committee of ASRM. Assessment and treatment of recurrent miscarriage. Fertil Steril. 2012; 98:1103–11.
20. Ford HB, Schust DJ. Recurrent pregnancy loss: causation, diagnosis, and therapy. Rev Obstet Gynecol. 2009; 2:76–83.
21. Brodin T, et al. FSH levels and pregnancy outcomes. Hum Reprod. 2013; 28:126–34.
22. van Rooij IA, et al. High FSH is an indication of ovarian aging. J Clin Endocrinol Metab. 2005; 90:1422–7.
23. Yu Ng EH, Ho PC. Polycystic ovaries and hypersecretion of luteinising hormone in infertility. Hum Reprod. 2000; 15:1497–502.
24. Regan L., et al. Luteinizing hormone and recurrent miscarriage. Br J Obstet Gynaecol. 1990; 97:1141–5.
25. Bussen S, Steck T. Hyperprolactinaemia and miscarriage. Arch Gynecol Obstet. 1997; 259:79–83.
26. Hirahara F, et al. Bromocriptine therapy reduces miscarriage. Fertil Steril. 1998; 70:246–52.
27. Korevaar TI, et al. Thyroid function and risk of pregnancy loss. JAMA. 2017; 317:562–71.
28. Poppe K, et al. Thyroid autoimmunity and reproductive failure. Endocr Rev. 2007; 28:102–32.
29. La Marca A, et al. AMH as ovarian reserve prediction. Hum Reprod Update. 2010; 16:113–30.
30. Steiner AZ, et al. AMH and early pregnancy loss. Fertil Steril. 2011; 96:478–83.
31. Montoya JG, Liesenfeld O. Toxoplasmosis and pregnancy. Lancet. 2004; 363:1965–76.
32. Singh S. Transplacental infection with Toxoplasma Gondii. Indian J Med Microbiol. 2003; 21:13–20.
33. Kwak-Kim J, et al. Immune dysregulation in recurrent miscarriage. Am J Reprod Immunol. 2010; 63:543–54.
34. Jauniaux E, et al. Pathology of the placenta in recurrent pregnancy loss. Hum Reprod. 2006; 21:2641–7.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
